Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals announces publication of pivotal data from SIVEXTRO (tedizolid phosphate) ESTABLISH-2 Clinical Trial in The Lancet Infectious Diseases


Friday, 6 Jun 2014 09:00am EDT 

Cubist Pharmaceuticals Inc:Says The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a Phase 3 clinical trial of investigational antibiotic SIVEXTRO (tedizolid phosphate).Developed for treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI). 

Company Quote

98.67
0.9 +0.92%
19 Dec 2014